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Janus kinases are important signaling proteins implicated in cytokine signaling. In particular, Janus kinase 3
(JAK3) has gained attention as a target for inhibition of the immune system, due to its importance for T and B
cell development and function. In this issue however, Haan et al. (2011) show that inhibition of JAK3 activity
may not be sufficient for this purpose.Table 1. Cytokine Receptors and the Involvement of JAK Kinases
Type Subgroup Receptors for JAK Kinase Usage
Type I Homodimeric EPO, TPO, GH, G-CSF JAK2
Type I Using the common beta
chain (CSF2Rb, CD131)
IL3, IL5, GM-CSF JAK2
Type I Using the gp130 chain
(IL6ST, CD130)
IL6, IL11, OSM, LIF JAK1, JAK2, TYK2
Type I Using the common gamma
chain(gc, IL2Rg, CD132)
IL2, IL4, IL7, IL9, IL15, IL21 JAK1, JAK3
Type II — IFNa, IFNb, IFNg, IL10, IL19,
IL20, IL22, IL24, IL28, IL29
JAK1, JAK2, TYK2
The receptors for EPO, TPO, GH, and G-CSF are homodimers; all other cytokine receptors are het-
erodimers containing a ligand-specific chain and a common chain used by different receptors.
JAK3 is required for signaling of the type I receptors that use the common gamma chain (gc).Janus kinases (JAKs) are cytosolic tyro-
sine kinases that associate with cytokine
receptors. Since cytokine receptor pro-
teins lack any enzymatic activity, they
are completely dependent on the tyrosine
kinase activity of the JAKs to initiate
signaling upon binding of the cytokines.
Based on different properties, domains,
and motifs, the cytokine receptors are
divided in fivemajor subgroups, as shown
in Table 1.
JAKs are thus critically important for
cytokine signaling in the immune system,
but are also required to regulate cell prolif-
eration, survival, development, and differ-
entiation of a variety of cells. Given the
importance of cytokine receptor signaling
for the development and functioning
of the hematopoietic system, it is not
surprising that both gain-of-function
mutations and loss-of-function mutations
of JAKs are implicated in human hemato-
logical diseases. Activating mutations in
JAK1, JAK2, and JAK3 have been identi-
fied as causes of hematological cancers,
while inactivating mutations of JAK3 and
TYK2 are known causes of immune
deficiency (Vainchenker et al., 2008).
Mutations in the IL7 receptor (IL7R
and the common gamma chain)- JAK3
complex are specifically important, as
they account for approximately 70%
of severe combined immunodeficiency
cases (Ghoreschi et al., 2009). Also it
was confirmed in mouse models that the
absence of JAK3 or the common gamma
chain leads to immunodeficiency due to
defects in both B cell and T cell develop-
ment and activation (Pesu et al., 2005).
Inactivation of Jak1 or Jak2 genes in
mice causes severe defects and results
in early lethality. In agreement with this,inactivating mutations in JAK1 or JAK2
have not been identified in immunodefi-
ciency patients, most likely because the
loss of these kinases would cause a
plethora of severe defects that would be
incompatible with life (Ghoreschi et al.,
2009).
From these insights in the role of JAK3
for the development and functioning of
the immune system, development of
JAK kinase inhibitors was initiated, with
possible applications for the treatment of
autoimmune diseases, inflammation, and
the prevention of organ transplant rejec-
tion (Changelian et al., 2003; Kudlacz
et al., 2004; Pesu et al., 2005). JAK3-
specific inhibitors were hypothesized to
be as effective as general JAK inhibitors
but less toxic, given the more restricted
expression of JAK3 and results from
knockout mice.
Previous attempts, however, to design
JAK3-specific inhibitors have not been
very successful. Initially, the inhibitor CP-
690,550 was designed as a JAK3-specific
inhibitor, but subsequent analysis of thisChemistry & Biology 18, March 25, 2011compound revealed it is also a potent
inhibitor of the other JAKs, including
JAK1 (Karaman et al., 2008). NIBR3049,
a novel JAK inhibitor recently described
to be more specific for JAK3, could be
a JAK3-specific inhibitor, as it has shown
more than 100-fold lower activity on the
other JAKs, based on in vitro kinase
assays (Thoma et al., 2011). Surprisingly,
this compound displayed low activity
in cellular assays, measuring cytokine-
induced signaling through receptors
dependent on the common gamma chain.
Based on these observations, Haan
et al. (2011) performed an in-depth anal-
ysis of the exact role of JAK3 inhibition
in cytokine receptor signaling. This work
clearly shows that an intact JAK3 protein
is strictly required for functioning of the
IL2 receptor (containing the IL2R beta
chain and common gamma chain). When
JAK3 is absent or when its expression
is decreased by siRNA-mediated knock-
down, activation of the receptor is not
possible. This is in agreement with
previous work that showed that mutationsª2011 Elsevier Ltd All rights reserved 277
Figure 1. Overview of the effect of JAK inhibitors on IL2 receptor signaling
In the IL2, heterodimeric receptor JAK1 is bound to the beta receptor and JAK3 is bound to the common gamma receptor. Note that the nonsignaling alpha
chain of the IL2 receptor is not shown in this graph. IL2 stimulation results in the activation of JAK1 and JAK3 through cross phosphorylation, and JAK1 also
phosphorylates STAT5. Work by Haan et al. (2011) shows that inhibition of JAK3 using a JAK3-specific inhibitor only slightly affects JAK1 and STAT5 activity,
and that a JAK inhibitor with JAK1 inhibitory activity is needed to fully inhibit JAK1 and STAT5 phosphorylation.
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ficking of the common gamma chain,
and without the presence of the common
gamma chain, the IL2-type receptors
(type I cytokine receptors using the
common gamma chain) cannot function
(Pesu et al., 2005). In contrast to this,
Haan et al. found that JAK3 kinase activity
is not strictly required for signaling of the
IL2 receptor (Figure 1). Expression of
a kinase-inactive JAK3 reduced activation
of downstream signaling proteins, but did
not completely abolish it. In addition,
specific inhibition of JAK3 kinase activity
did not significantly reduce STAT5 phos-
phorylation (Haan et al., 2011). While
JAK3 kinase activity is thus not essential,
JAK1 kinase activity was indispensable,
and inhibition of JAK1 or expression of
a kinase inactive JAK1 protein completely
abolished signaling (Figure 1).
These data, together with early data
illustrating the low activity of a JAK3-
specific inhibitor, question the potency
of JAK3-specific inhibitors for modulating
the immune response. In contrast, JAK278 Chemistry & Biology 18, March 25, 2011inhibitors with activity against JAK3 but
also JAK1 show potent inhibitory activity
on cytokine receptor signaling. It remains
to be investigated if these inhibitors
will pass or fail in ongoing clinical trials
with respect to activity and, importantly,
toxicity.
Based on previous studies that showed
that the association of JAK3 with the
common gamma chain is required for
its transport to the plasma membrane
and on the data presented here, which
confirm that siRNA-mediated knockdown
of JAK3 is highly effective in inhibiting
IL2-induced signaling on the IL2 receptor,
one could speculate that compounds
that interfere with the binding of JAK3 to
the common gamma chain would be
effective and selective for inhibiting
gamma chain-dependent cytokine recep-
tor signaling. The development of such
inhibitors that target protein-protein inter-
actions is, however, not trivial and may
not be needed if the general JAK inhibitors
show potent activity and a good safety
profile.ª2011 Elsevier Ltd All rights reservedREFERENCES
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